Program of USCACA 2014 Annual Meeting1

US Chinese Anti-Cancer Association Annual Meeting at ASCO 2014
6:30 - 9:00 pm
May 30, 2014
Hilton Chicago, Salon A-5, Lower Level
720 South Michigan Avenue, Chicago, 60605

Dear Colleagues,
On behalf of the organizing committee, we would like to cordially invite you to attend the sixth US Chinese Anti-Cancer Association (USCACA) Annual Meeting at ASCO 2014 at 6:30 - 9:00 pm on May 30, 2014 in the Hilton Chicago Hotel, Chicago. The meeting will highlight collaboration among USCACA, Chinese Anti-Cancer Association (CACA), Chinese Society of Clinical Oncology (CSCO), China Food and Drug Administration (CFDA), National Foundation of Cancer Research (NFCR), Tyler Institute for Genomic Medicine (TIGM), and Xinxiang Medical University, China, and several major Chinese Pharmaceutical companies. The meeting will also update recent successes and explore opportunities to further foster translational research and facilitating oncology translational research and early clinical development. Your presence and presentation will undoubted enhance its scientific value and influence.

Please kindly RSVP to: 2014conference@uscaca.org (RSVP form on page 4)

We look forward to hearing from your confirmation.

Sincerely yours,

Shi-Yuan Cheng, PhD, President
Li Yan, MD, PhD, Managing Director
Wei Zhang, PhD, Board Director

Program
6:30 - 9:00 pm, May 30, 2014; Hilton Chicago, Salon A-5, Lower Level, 720 South Michigan Avenue, Chicago, 60605
6:30 - 6:35 Introduction and Welcome -Dr. Yunguang Tong, USCACA Executive Committee, Annual Meeting Chair
6:35 - 6:45 USCACA Presidential Address - Dr. Shi-Yuan Cheng, President, USCACA
6:45 - 6:55 Remark on CSCO-USCACA Collaboration and Preview of CSCO 2014 Annual Meeting - Dr. Yilong Wu, Council Chairman of Chinese Society for Clinical Oncology (CSCO)
6:55 - 7:30 Genomic Medicine in Oncology R&D and its Impact on Early Development in China
6:55-7:10 Single Cell Sequencing in Oncology
- Dr. Xiaoliang Sunney Xie, Harvard University
7:10-7:20 Multi-Omics Solutions for Cancer Research
-Dr Zonghui Peng, BGI Tech
7:20-7:30 Master Meets Cluster: Developing Personalized Medicine for Lung Cancer Patients
- Dr. Yilong Wu, Guangdong General Hospital
- Dr. Vali Papadimitrakopoulou，MD Anderson Cancer Center
7:30 - 8:00 Panel Discussion: Genomic Medicine in Oncology R&D and its Impact on Early Development in China - Dr. Michael Shi, Executive Committee, USCACA
7:30-7:50 Update from USCACA-CSCO-CFDA Joint New Cancer Drug Development Committee: Draft Biomarker Guideline of China CFDA
- Dr. Li Xu, Executive Committee, USCACA
- Dr. Roger Luo, Executive Committee, USCACA
- Dr. Vali Papadimitrakopoulou，MD Anderson Cancer Center
- Dr. Margaret Dugan, Senior Vice President, Novartis Oncology
- Dr. Chris Takimoto, Vice President, Head of Oncology TM & ED, Janssen Pharmaceutical Companies
- Dr. Jin Li, Fudan University
- Dr. Hua Mu, Senior Vice President, Global Head of Product Development Business Unit, WuXi AppTec
- Dr. Yilong Wu, Guangdong General Hospital
7:50-8:00 USCACA-Hengrui Early Phase Clinical Research Training Scholarship
- Dr. Li Yan, Executive Director, USCACA
- Dr. Li Xu, SVP, Jiangsu Hengrui Oncology; Executive Committee USCACA
8:00 - 8:05 Closing remarks - Dr. Shi-Yuan Cheng, President, USCACA
8:05 - 9:00 Networking Time

US Chinese Anti-Cancer Association
(www.uscaca.org)

U.S. Chinese Anti-Cancer Association (USCACA美中抗癌协会) is a non-profit professional organization founded in 2009. With members from academia, industry and government, USCACA facilitates collaboration among cancer research and physicians in the United States and China. Our current focus is on expediting novel cancer drug development by fostering clinical trial networks, sharing best practices and knowledge of clinical trial, and providing education and training opportunities. USCACA collaborates with Chinese Anti-Cancer Association (CACA 中国抗癌协会), Chinese Society for Clinical Oncology, and other professional associations. Our mandate is to improve cancer treatment through research, education, and collaboration.

USCACA 2014 Annual Conference Organizing Committee

Yunguang Tong, Cedars-Sinai Med CTR/UCLA
Roger Luo, Janssen Pharmaceutical Co
Michael Shi, Novartis Oncology
Lifang Hou, Northwestern University
Shi-Yuan Cheng, Northwestern University
Li Yan, GlaxoSmithKline
Wancai Yang, Xinxiang Medical University
Helen Chen, NCI
Weimin Qi, Biocare Medical
Wei Zhang, MD Anderson Cancer Center
Dongfeng Tan, MDACC
Li Xu, Jiangsu Hengrui Oncology
Pascal Qian, Novartis Oncology
Xiaoxiang Chen, Boehringer-Ingelheim
Yun Dai, Virginia Commonwealth University
Wei Zhang, University of Illinois at Chicago